A former SAC Capital Advisors trader wants to cite in court some 2012 testimony given by the hedge fund's founder Steven Cohen, claiming it rebuts the government's case.» Read More
Oct 30- Parexel International Corp's shares fell as much as 18 percent after the drug research services provider said it struggled to win new contracts when rivals reported strong results and raised their forecasts.
*IBM climbs on buyback announcement and lifts Dow. NEW YORK, Oct 29- The Dow and S&P 500 ended at record highs on Tuesday after economic data supported views that the Federal Reserve would keep its stimulus intact for several months and IBM rallied after the company announced a stock buyback. IBM gave the biggest boost to the Dow, which led the day's gains.
Stocks finished near session highs Tuesday, with the S&P 500 touching a fresh high and the Dow within 50 points of an all-time record, as investors looked ahead to the Federal Reserve's announcement.
*IBM climbs on buyback, dividend announcement. *Apple down a day after reporting results; JPMorgan shares slip. NEW YORK, Oct 29- U.S. stocks rose on Monday, extending the S&P 500' s string of record highs, as economic data supported views the Federal Reserve will keep its stimulus intact for several months and IBM gained after it announced a buyback.
Take a look at some of Tuesday's midday movers:
*IBM climbs on buyback, dividend announcement. Federal Reserve will keep its stimulus measures intact for several months, while gains in Pfizer and IBM helped the Dow.
Political embarrassment over Obamacare has not spilled over into the markets yet, but it could if matters continue to worsen.
*Apple shares volatile following results, outlook. NEW YORK, Oct 29- U.S. stocks rose modestly on Tuesday, with the market's upward momentum continuing as the S&P 500 hit another record high and drug company Pfizer rallied on its results. Volatile movement by Apple Inc following its results also capped gains.
*Apple edges higher after results, revenue outlook. *Aetna earnings miss expectations, U.S. NEW YORK, Oct 29- U.S. stock index futures pointed to a flat open on Tuesday, suggesting the market's recent rally may have run out of steam as earnings fail to be another reason to buy with stocks near record highs.
U.S. stock index futures held their gains Tuesday, with the S&P 500 poised to hit a fresh high, despite a weaker-than-expected retail sales report and ahead of the Federal Reserve's two-day meeting.
*Apple shares rise after first-quarter revenue forecast. NEW YORK, Oct 29- U.S. stock index futures were little changed on Tuesday, suggesting the market's recent rally may have run out of steam as earnings fail to spur optimism with stocks near record highs.
Some of the names on the move ahead of the open.
Oct 29- Pfizer Inc reported better-than-expected third-quarter earnings on Tuesday, helped by costs cuts and growing sales of recently approved cancer medicines. The largest U.S. drugmaker said it earned $2.59 billion, or 39 cents per share in the quarter, compared with $3.21 billion, or 43 cents per share, in the year-earlier period.
Oct 29- Pfizer Inc reported better-than-expected third-quarter earnings on Tuesday, helped by costs cuts and growing sales of recently approved cancer medicines. The largest U.S. drugmaker said it earned $2.59 billion, or 39 cents per share, in the quarter, compared with $3.21 billion, or 43 cents per share, in the year-earlier period.
Pfizer reported quarterly earnings that beat analysts' expectations on Tuesday, but it lowered its guidance for its full-year guidance.
As the Fed begins its two-day policy meeting Tuesday, markets will get a look at how consumers behaved just before the government shut down.
Barbara Ryan, FTI Consulting managing director, breaks down the pharmaceutical company's earnings and weighs in on two promising drugs in the pipeline, as the company ramps up research and development.
The high likelihood that the Federal Reserve will maintain current interest rate policy means stock buybacks likely will remain in vogue.
Bulls face a trio of challenges: The Fed, earnings from some big names and delayed data due to the shutdown. Will they keep running or lie down?
Oct 23- Bristol-Myers Squibb Co reported better-than-expected quarterly earnings, fueled by strong sales of cancer and diabetes drugs, but weak demand for its new Eliquis blood clot medicine dampened investor enthusiasm.